Thomas Moench

Thomas is an infectious disease physician/scientist and served on the faculty of JHU School of Medicine for over 10 years. As Chief Medical Officer at Mapp, he oversaw the clinical development of ZMapp, a cocktail of 3 mAbs for treatment of Ebola, as well as the preclinical development and clinical study of MB66, a vaginal film loaded with two anti-viral mAbs. He was the Principle Investigator (PI) of over $144M in BARDA funding for the development of ZMapp and co-PI of a $13.3M NIAID-sponsored multicenter microbicide program that funded the MB66 work. As such, he has experience in both clinical development and the industrialization of biologics as well as drug-device combinations for infectious diseases.